# A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

> **NCT00724841** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gemin X** · enrollment: 1 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Obatoclax Mesylate
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00724841
- **Lead sponsor:** Gemin X
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2008-07
- **Final completion:** 2010-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study terminated prematurely due to financial contraints.
- **Last updated:** 2016-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724841, "A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00724841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*